Protocol Ledger

NCT06091865 · Phase III · RECRUITING

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

Interventional Phase III clinical trial protocol NCT06091865 sponsored by Regeneron Pharmaceuticals in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-12-13 Enrollment: 904 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06091865
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)904 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06091865
Protocol FieldVerified Registry Value
NCT IdentifierNCT06091865
Consolidated Lead SponsorRegeneron Pharmaceuticals
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment904 participants (ESTIMATED)
Registered Start Date2023-12-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Regeneron Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI